Aanjaneya Lifecare is currently trading at Rs. 555.45, up by 17.00 points or 3.16% from its previous closing of Rs. 538.45 on the BSE.
The scrip opened at Rs. 535.00 and has touched a high and low of Rs. 558.80 and Rs. 535.00 respectively. So far 6501 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 575.00 on 02-Feb-2012 and a 52 week low of Rs. 224.00 on 27-May-2011.
Last one week high and low of the scrip stood at Rs. 575.00 and Rs. 486.00 respectively. The current market cap of the company is Rs. 692.97 crore.
The promoters holding in the company stood at 60.43% while Institutions and Non-Institutions held 4.46% and 35.12% respectively.
Drug maker, Aanjaneya Lifecare has acquired Hyderabad-based Apex Drugs and Intermediates (ADIL). The acquisition was valued at Rs 250 crore with debt of Rs 185 crore and equity dilution of Rs 65 crore. The Mumbai-based company has acquired ADIL’s assets, businesses, clients, licensees, employees and has merged both the companies' operations.
The company will leverage the strong relations of ADIL developed in Asia, Europe, UAE and Latin America for exports. The acquisition will help Aanjaneya Lifecare to widen its product portfolio in various therapeutic segments including AIDS, Diabetes and central nervous system.
Aanjaneya Lifecare is a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities. It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: